Delivery of compounds for the treatment of Parkinsons through an inhalation route
First Claim
1. A composition for delivery for of an antiparkinsonian drug comprising a condensation aerosola) formed by volatilizing an antiparkinsonian drug under conditions effective to produce a heated vapor of the drug and condensing the heated vapor of the drug to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% antiparkinsonian drug degradation products, and c) wherein the aerosol MMAD is less than 3 microns.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of compounds for the treatment of Parkinsons through an inhalation route. Specifically, it relates to aerosols containing antiparkinsonian drugs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antiparkinsonian drug. In a method aspect of the present invention, an antiparkinsonian drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antiparkinsonian drug to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antiparkinsonian drug through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antiparkinsonian drug; and, b) a device that forms an antiparkinsonian drug containing aerosol from the composition, for inhalation by the mammal.
-
Citations
16 Claims
-
1. A composition for delivery for of an antiparkinsonian drug comprising a condensation aerosol
a) formed by volatilizing an antiparkinsonian drug under conditions effective to produce a heated vapor of the drug and condensing the heated vapor of the drug to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less than 5% antiparkinsonian drug degradation products, and c) wherein the aerosol MMAD is less than 3 microns.
-
8. A method of producing an antiparkinsonian drug in an aerosol form comprising:
-
a) volatilizing an antiparkinsonian drug under conditions effective to produce a heated vapor of the drug, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of the drug comprising less than 5% drug degradation products and an aerosol having an MMAD less than 3 μ
m.- View Dependent Claims (9, 10, 11, 12, 13, 14, 15, 16)
-
Specification